Literature DB >> 25516889

Recurrent PRDM10 gene fusions in undifferentiated pleomorphic sarcoma.

Jakob Hofvander1, Johnbosco Tayebwa2, Jenny Nilsson2, Linda Magnusson2, Otte Brosjö3, Olle Larsson4, Fredrik Vult von Steyern5, Nils Mandahl2, Christopher D M Fletcher6, Fredrik Mertens2.   

Abstract

PURPOSE: Undifferentiated pleomorphic sarcoma (UPS) is defined as a sarcoma with cellular pleomorphism and no identifiable line of differentiation. It is typically a high-grade lesion with a metastatic rate of about one third. No tumor-specific rearrangement has been identified, and genetic markers that could be used for treatment stratification are lacking. We performed transcriptome sequencing (RNA-Seq) to search for novel gene fusions. EXPERIMENTAL
DESIGN: RNA-Seq, FISH, and/or various PCR methodologies were used to search for gene fusions and rearrangements of the PRDM10 gene in 84 soft tissue sarcomas.
RESULTS: Using RNA-Seq, two cases of UPS were found to display novel gene fusions, both involving the transcription factor PRDM10 as the 3' partner and either MED12 or CITED2 as the 5' partner gene. Further screening of 82 soft tissue sarcomas for rearrangements of the PRDM10 locus revealed one more UPS with a MED12/PRDM10 fusion. None of these genes has been implicated in neoplasia-associated gene fusions before.
CONCLUSIONS: Our results suggest that PRDM10 fusions are present in around 5% of UPS. Although the fusion-positive cases in our series showed the same nuclear pleomorphism and lack of differentiation as other UPS, it is noteworthy that all three were morphologically low grade and that none of the patients developed metastases. Thus, PRDM10 fusion-positive sarcomas may constitute a clinically important subset of UPS. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25516889     DOI: 10.1158/1078-0432.CCR-14-2399

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

1.  Identification of Novel Fusion Transcripts in Undifferentiated Pleomorphic Sarcomas by Transcriptome Sequencing.

Authors:  Biqiang Zheng; Shuirong Zhang; Weiluo Cai; Jian Wang; Ting Wang; Ning Tang; Yingqiang Shi; Xiaoying Luo; Wangjun Yan
Journal:  Cancer Genomics Proteomics       Date:  2019 Sep-Oct       Impact factor: 4.069

Review 2.  The emerging complexity of gene fusions in cancer.

Authors:  Fredrik Mertens; Bertil Johansson; Thoas Fioretos; Felix Mitelman
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

3.  Gene fusion detection in formalin-fixed paraffin-embedded benign fibrous histiocytomas using fluorescence in situ hybridization and RNA sequencing.

Authors:  Charles Walther; Jakob Hofvander; Jenny Nilsson; Linda Magnusson; Henryk A Domanski; David Gisselsson; Johnbosco Tayebwa; Leona A Doyle; Christopher D M Fletcher; Fredrik Mertens
Journal:  Lab Invest       Date:  2015-06-29       Impact factor: 5.662

Review 4.  Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themes.

Authors:  Fredrik Mertens; Cristina R Antonescu; Felix Mitelman
Journal:  Genes Chromosomes Cancer       Date:  2015-12-18       Impact factor: 5.006

5.  Serum lactate dehydrogenase as a novel prognostic factor for patients with primary undifferentiated pleomorphic sarcomas.

Authors:  Qiaowei Lin; Zhengwang Sun; Lin Yu; Qifeng Wang; Ping Zhu; Yihan Jiang; Yangbai Sun; Wangjun Yan
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-29       Impact factor: 4.553

6.  Overlapping morphological, immunohistochemical and genetic features of superficial CD34-positive fibroblastic tumor and PRDM10-rearranged soft tissue tumor.

Authors:  Florian Puls; Jodi M Carter; Nischalan Pillay; Thomas A McCulloch; Vaiyapuri P Sumathi; Pehr Rissler; Henrik Fagman; Magnus Hansson; Fernanda Amary; Roberto Tirabosco; Linda Magnusson; Jenny Nilsson; Adrienne M Flanagan; Andrew L Folpe; Fredrik Mertens
Journal:  Mod Pathol       Date:  2021-12-30       Impact factor: 7.842

7.  Undifferentiated Sarcomas in Children Harbor Clinically Relevant Oncogenic Fusions and Gene Copy-Number Alterations: A Report from the Children's Oncology Group.

Authors:  Theodore W Laetsch; Angshumoy Roy; Lin Xu; Jennifer O Black; Cheryl M Coffin; Yueh-Yun Chi; Jing Tian; Sheri L Spunt; Douglas S Hawkins; Julia A Bridge; D Williams Parsons; Stephen X Skapek
Journal:  Clin Cancer Res       Date:  2018-04-24       Impact factor: 12.531

8.  A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases.

Authors:  Rita Alaggio; Lei Zhang; Yun-Shao Sung; Shih-Chiang Huang; Chun-Liang Chen; Gianni Bisogno; Angelica Zin; Narasimhan P Agaram; Michael P LaQuaglia; Leonard H Wexler; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

9.  Down-regulation of PR/SET domain 10 underlies natural killer cell dysfunction in hepatocellular carcinoma.

Authors:  Jiantao Han; Chao Ke; Bin Jiang; Hongjian Zhou; Hanbin Xu; Xingwang Xie
Journal:  Clin Exp Immunol       Date:  2021-10-10       Impact factor: 4.330

Review 10.  The duality of PRDM proteins: epigenetic and structural perspectives.

Authors:  Federico Di Tullio; Megan Schwarz; Habiba Zorgati; Slim Mzoughi; Ernesto Guccione
Journal:  FEBS J       Date:  2021-05-19       Impact factor: 5.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.